Indeed, such approaches have been tested using a specific inhibitor of the MDM2-p53 axis (Nutlin-3a), which has been shown to induce p53-mediated cell death in retinoblastoma cell lines33 and xenograft models of retinoblastoma alone or in combination with systemic Topotecan.34 This evidence concerns the gene MDM2 and retinoblastoma.